MSN
MSN (Moesin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Renal cell carcinoma, Basal cell carcinoma and 3 more.
Overview
Ezrin-radixin-moesin (ERM) family protein that connects the actin cytoskeleton to the plasma membrane and thereby regulates the structure and function of specific domains of the cell cortex. Tethers actin filaments by oscillating between a resting and an activated state providing transient interactions between moesin and the actin cytoskeleton. Once phosphorylated on its C-terminal threonine, moesin is activated leading to interaction with F-actin and cytoskeletal rearrangement.
Open Targets scores its association with cancer at 0.57 (direct and indirect evidence; datatypes affected pathway 0.76, literature 0.98, genetic association 0.04, somatic mutation 0.47, animal model 0.62). IntOGen calls it a driver in 4 cohorts (1 activating, 2 loss-of-function), covering Basal Cell Carcinoma, Renal Clear Cell Carcinoma, Oesophageal Adenocarcinoma, Oesophageal Squamous Cell Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MSN (Moesin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Renal cell carcinoma, Basal cell carcinoma and 3 more.
- 1 · What it is
MSN (Moesin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Renal cell carcinoma, Basal cell carcinoma and 3 more.
- 2 · What goes wrong in cancer
Ezrin-radixin-moesin (ERM) family protein that connects the actin cytoskeleton to the plasma membrane and thereby regulates the structure and function of specific domains of the cell cortex.
- 3 · How drugs use it
No product in this corpus aims at MSN yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:7373 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P26038 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000147065 (association with cancer (MONDO_0004992) 0.57; (GraphQL API, CC0)); IntOGen MSN (driver in 4 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Ezrin-radixin-moesin (ERM) family protein that connects the actin cytoskeleton to the plasma membrane and thereby regulates the structure and function of specific domains of the cell cortex. Tethers actin filaments by oscillating between a resting and an activated state providing transient interactions between moesin and the actin cytoskeleton. Once phosphorylated on its C-terminal threonine, moesin is activated leading to interaction with F-actin and cytoskeletal rearrangement. These rearrangements regulate many cellular processes, including cell shape determination, membrane transport, and signal transduction. The role of moesin is particularly important in immunity acting on both T and B-cells homeostasis and self-tolerance, regulating lymphocyte egress from lymphoid organs. Modulates phagolysosomal biogenesis in macrophages. Location: Cell membrane; Cytoplasm, cytoskeleton; Apical cell membrane; Cell projection, microvillus membrane (UniProt). Locus Xq12 (HGNC).
- Oesophageal cancer: IntOGen driver in 2 cohorts (ESCA, ESCC)
- Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
- Basal cell carcinoma: IntOGen driver in 1 cohort (BCC)
- Clear cell renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
- Oesophageal and junctional adenocarcinoma: IntOGen driver in 1 cohort (ESCA)
- Oesophageal squamous cell carcinoma: IntOGen driver in 1 cohort (ESCC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"MSN" OR ABSTRACT:"MSN" OR TITLE:"moesin" OR ABSTRACT:"moesin" OR TITLE:"Moesin" OR ABSTRACT:"Moesin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MSN, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetRAP1GDS1
Shares Oesophageal squamous cell carcinoma, Clear cell renal cell carcinoma, Renal cell carcinoma, Oesophageal cancer.
- TargetARHGEF10L
Shares Clear cell renal cell carcinoma, Basal cell carcinoma, Renal cell carcinoma, IntOGen.
- TargetZNF750
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
- TargetTGFBR1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
- TargetATG7
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
- TargetCANT1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetZNF208
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetGRM3
Shares Oesophageal and junctional adenocarcinoma, Renal cell carcinoma, Oesophageal cancer, IntOGen.